KLF13 and atrial fibrillation: To summarize, our research suggests that EVs derived from human cardiac explant cells (CDCs) are capable of transporting XR_001793654.1, a lncRNA that can bind to miR-107-3p and mitigate its inhibitory effect on the target gene KLF13, consequently reducing the impact of AF (Figure 7).